Can-Fite BioPharma announced that it is doing all the preparatory work for an FDA investigational new drug, or IND, submission for the treatment of pancreatic carcinoma with Namodenoson.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANF: